Compare PUMP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PUMP | PCRX |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2017 | 2010 |
| Metric | PUMP | PCRX |
|---|---|---|
| Price | $16.13 | $22.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $14.14 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 4.4M | 492.8K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 100.76 | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $1,269,158,000.00 | $541,533,000.00 |
| Revenue This Year | N/A | $6.78 |
| Revenue Next Year | $15.61 | $8.54 |
| P/E Ratio | ★ N/A | $325.57 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $4.51 | $18.80 |
| 52 Week High | $18.50 | $27.64 |
| Indicator | PUMP | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.15 | 40.50 |
| Support Level | $14.90 | $22.13 |
| Resistance Level | N/A | $24.20 |
| Average True Range (ATR) | 1.05 | 1.29 |
| MACD | -0.15 | -0.32 |
| Stochastic Oscillator | 35.28 | 10.26 |
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.